attract risk/reward upgrad outperform
upgrad outperform work dark period
extens patent expir hamper compani abil
grow period near end combin new product
stori multipl market pipelin asset believ may
underappreci lead us upgrad share outperform
neutral increas target price adjust
ep estim
growth driver look encourag
wait clariti outlook feel initi
impact lyrica loss exclus guidanc behind us
look growth driven time-frame market
product ibranc xeljanz xtandi well pipelin asset
tanezumab tafamidi vaccin addit encourag
appear target pipeline-boost bolt-on acquisit
larger deal often disrupt given multipl product
potenti improv growth outlook come year
multipl pipelin catalyst line come month addit
rais target price target price
blend discount cash flow dcf valuat rel valuat
dcf base wacc termin growth
rel valuat base new ep
main risk view commerci clinic trial setback
valuat metric
number share
price month
neutral outperform
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
pfizer inc biopharmaceut compani engag
discoveri develop manufactur sale medicin
price jan rate neutral outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
grey sky valuat base lower sale ibranc
prevnar xtandi eliqui compar current base case
assumpt also model lower oper margin
base case assumpt grey sky valuat base dcf
driven wacc termin valu
blue sky valuat base greater sale
ibranc prevnar xtandi eliqui compar current base case
assumpt also model higher oper margin
base case assumpt blue sky valuat base dcf
driven wacc termin valu
 close
dark period patent
expir new growth
close work inflect point exit period multipl product
lose exclus prepar enter new growth phase lipitor patent expir
singl biggest blow sinc time major blockbust enbrel
outsid us viagra also lost patent protect sale
lyrica peak ahead us patent loss expect june figur howev
newer product step replac lost revenu product
ibranc eliqui xeljanz xtandi amongst carri torch
maintain sever year market exclus pipelin also
hold potenti recent year numer novel agent line
extens hold blockbust potenti figur assum
product success compani suggest mani opportun
shot goal near horizon move needl even compani
year cap loss blockbust lyrica
us million unless otherwis state
charl martineau univers toronto figur product line-up revenu potenti import
data readout come month
mm
mm
intermedi high risk ebc
note analysi product portfolio struggl obtain
accur consensu estim beyond see key
growth driver result compar estim consensu
product howev believ posit clinic data strong commerci execut
core product would lead upsid estim believ
current street estim product
market product room growth
opportun clear reacceler
ibranc clear success stori sinc launch global
sale exceed howev even degre growth product
face challeng introduct new competitor earli
market satur us figur resolut reimburs negoti
europ limit ex-u sale growth fy product show global sale growth
although us verzenio appear reason
competitor physician spoken remain comfort ibranc profil
continu expect give ibranc domin market share
charl martineau univers toronto figur trx ibranc kisqali verzenio sinc launch
weekli trx ibranc kisqali verzenio sinc respect launch
despit ibranc strong uptak advanc breast cancer close follow
work compani move drug earli breast cancer notabl
penelop palla trial drive next level growth
product trial enrol faster expect current expect read
although event driven trial exact time may chang success
trial could greatli expand ibranc potenti patient popul bring patient
onto treatment earlier cours diseas given ibranc safeti profil
lead longer durat therapi compani comment
new patient per year ibranc current indic number
moderate-high risk patient could candid ibranc adjuv
given ibranc mechan action biomark data seen
earlier trial expect drug deliv favor result two trial help
drive outer year estim ibranc mechan would also suggest may
effect tumor outsid breast cancer wait data least one
tumor type assign revenu opportun figur
recoveri reimburs challeng new indic help
xtandi anoth drug face growth challeng see
significantli greater opportun go forward street current product
initi brought compani acquisit mediv
product seen strong volum growth net sale less expect
given need greater patient assist prostat cancer foundat unabl
support patient much previou year issu resolv
xtandi revenu fy importantli product
approv broader indic base result prosper studi pre-
metastat set data embark studi xtandi lupron pre-metastat
set also expect provid anoth boost franchis
sinc complet mediv deal acquir right xtandi
comment success much larger pre-metastat set alon would like make
acquisit success life cycl manag program xtandi allow
total address popul essenti doubl metastat
set alon figur assum abl continu drive xtandi messag
urologist would anticip continu acceler xtandi sale path
product continu grow newer indic even zytiga face gener
competit date entri zytiga gener us meaning
impact xtandi prescript volum mainli taken share brand zytiga
figur estim preval incid rate variou form prostat cancer nih
local form prostat cancer
biochem failur local therapy/ris
non-metastat castrate-resist form prostat cancer nmcrpc
biochem failur hormon therapi
hormone-sensit metastat form prostat cancer
metastat castration-resist form prostat cancer mcrpc
asymptomatic/minim symptomat mcrpc
treat progress chemotherapi
symptomat mcrpc treat
progress chemotherapi
mcrpc progress on/aft first-lin chemotherapi
incid occur diagnosi prostat cancer
incid deriv progress earlier clinic state
nation institut
figur zytiga xtandi weekli trx sinc oct
zytiga xtandi weekli
ulcer coliti indic boost xeljanz jak enter ra
anoth import market product receiv boost expand
indic oral jak inhibitor xeljanz product alreadi approv
rheumatoid arthriti psoriat arthriti may receiv fda approv use
moderate-sever ulcer coliti uc oral option treat uc meaning
physician patient interest drug although like take time see
full commerci impact given gener level comfort physician current
inject infus option fy xeljanz sale reflect growth
vs fy
time xeljanz face competit oral jak inhibitor
come year core rheumatoid arthriti indic make uptak uc import
sustain growth franchis four key market product discuss
xeljanz one least amount time left like
face direct gener competit expect gener version xeljanz enter us
market
figur current statu oral jak inhibitor market
indic
critic partner bristol-my squibb past
robust life-cycle manag program place eliqui take advantag
potenti opportun product outsid current indic stroke prevent
atrial fibril spaf venou thromboembol vte treatment prevent
howev spaf clearli singl largest opportun partner done
impress job continu gain share market product overtaken
warfarin market leader oral anticoagul space although remain
larg market opportun still ahead given much share warfarin still hold figur
figur weekli trx market share anti-coagul drug sinc xarelto
weekli trx market share anti-coagul drug sinc xarelto launch
risk eliqui uptak could stronger competit xarelto product
indic expand cover patient coronari arteri diseas peripher
arteri diseas base result compass studi could impact
doctor switch xarelto use spaf well although market remain
larg enough product continu grow see gener competit
sever pipelin product come
tanezumab intrigu opportun given opioid epidem
recent data seen late stage pipelin nerv
growth factor inhibitor tanezumab partnership eli lilli
phase studi alreadi readout includ top-line data second studi
releas week expect addit trial readout throughout cours
potenti fda file given opioid epidem think tanezumab
key concern class drug potenti treatment-rel rapidli
progress osteoarthr rpoa rare syndrom lead joint destruct
two phase studi osteoarthr readout demonstr
believ accept rate rpoa respect especi given
lack safe effect altern patient popul figur
need non-opioid altern treat chronic pain
howev import data readout remain long-term safety/efficaci studi
osteoarthr expect studi provid long-term safeti data
particularli respect rpoa head-to-head efficaci data multipl
commonly-us non-steroid anti-inflammatori drug figur given product
histori would like see definit safeti efficaci data get
excit believ could signific upsid cs consensu estim
product profil hold
note lilli profit split collabor tanezumab
book global revenu compani record sg expens
make quarterli payment lilli true-up profit split
also entitl potenti futur payment variou development regulatori
commerci mileston
toler abuse/depend potenti
charl martineau univers toronto figur phase studi tanezumab across multipl indic involv patient
efficaci safeti subcutan tanezumab
titrat dose regimen subject moder
sever osteoarthr hip knee
studi analges efficaci safeti
subcutan tanezumab subject
osteoarthr hip knee
long term safeti efficaci studi tanezumab
subject osteoarthr hip knee
patient
phase studi tanezumab chronic back
long term safeti efficaci studi tanezumab
japanes adult subject chronic back
phase studi efficaci safeti
tanezumab patient cancer pain due bone
toplin
toplin
recrut
recrut
recrut
diseas area increasingli focus
tafamidi focu
investor becom interest tafamidi follow practice-chang data
phase attr-act transthyretin cardiomyopathi ttr-act august
esc tafamidi previous underappreci asset alreadi
rebuf twice fda initi refuse-to-fil letter later complet
respons letter seek evid efficaci relat condit transthyretin
amyloid polyneuropathi tafamidi alreadi approv vyndaqel europ
sever ou market treat transthyretin amyloid polyneuropathi well
japan sole hered form condit model unadjust
adjust sale model tafamidi
diagnosi low physician educ could significantli improv market
opportun actual number patient transthyretin cardiomyopathi ttr-cm
present unknown expert believ condit underdiagnos
awar diseas among cardiologist low ttr-cm patient often
misdiagnos hypertens heart failur patient estim less
attr cardiomyopathi patient diagnos believ preval like
substanti higher compani expect engag physician educ particularli
among cardiologist like treat patient bring greater awar
could potenti increas diagnosi particularli wild-typ group see
inform
transthyretin transport protein four subunit natur circul blood
transthyretin becom unstabl misfold lead format amyloid
deposit heart peripher nervou system result condit call
transthyretin amyloidosi abnorm build-up amyloid deposit heart lead
two type transthyretin cardiomyopathi ttr-cm ttr famili amyloid
cardiomyopathi ttr-fac hereditari form diseas wild-typ ttr
cardiomyopathi wild-typ ttr-cm non-hereditari form diseas also
sometim refer senil system amyloidosi ssa type ttr-cm
share common pathophysiolog ttr tetram destabil lead amyloid
deposit heart result cardiac symptom
hereditari ttr-fac gener occur patient
preval mutat ttr-fac affect primarili african-american
peopl african descent world-wide mutat lead ttr-cm
identifi literatur search estim us preval
ttr-fac alon could older patient total preval
could higher
wild-typ ttr-cm usual occur patient primarili affect
male patient lack genet marker diagnosi wild-typ ttr-
cm even difficult diagnosi ttr-fac wild-typ ttr
literatur suggest patient age older could wild-typ ttr
data esc increas excit tafamidi opportun releas
pivot tafamidi data attr cardiomyopathi european societi
cardiolog annual meet data show mortal reduct
reduct cv-relat hospit patient treat tafamidi
better physician investor spoke ahead esc expect
indic
like cover wild-typ well hereditari
cardiomyopathi alnylam ioni drug may compet tafamidi
drug target famili amyloid polyneuropathi fap patient cover smaller
polyneuropathi fap impact peripher nerv heart underli
pathophysiolog build-up amyloid deposit potenti
competit product
price could us icer evalu effect valu
inotersen patisiran indic estim mean health care cost
per untreat patient hattr yet comment
us price tafamidi cardiomyopathi suggest price like
greater per year per patient price drug price europ
japan polyneuropathi indic
juli pdufa tafamidi submit two tafamidi applic
fda base two differ dosag form meglumin salt free acid tafamidi
meglumin form mg capsul grant prioriti review action date
fda decis juli tafamidi free acid form grant
month standard review action date compani also
comment activ discuss fda agenc potenti
reconsid drug polyneuropathi indic receiv previous
charl martineau univers toronto figur preval transthyretin amyloidosi
multipl approach gene therapi pipelin
sever approach on-going gene therapi either intern
collabor variou collabor acquisit
evalu gene
hemophilia
partnership sangamo hemophilia type partnership spark
hemophilia given size opportun think gene therapi program
could nice addit drive futur growth model current incorpor
risk-adjust sale two program provid room
signific upsid given potenti size market
hemophilia gene therapi smid cap biotech team estim global
market peak opportun could annual incid basi
post market satur preval popul potenti upsid dose
patient pre-exist aav neutral antibodi inhibitor preval
hemophilia us global hemophilia patient
address market
hemophilia gene therapi smid cap biotech team estim global
market peak opportun could approach annual incid
basi post market satur preval popul potenti upsid dose
patient pre-exist aav neutral antibodi inhibitor preval
incid hemophilia significantli smaller hemophilia us
patient hemophilia global
patient address market
accord smid cap biotech team dmd gene therapi total
address market potenti global incid opportun assum
price compar exist product year durabl incid rate
male birth us exondi approv disease-modifi
product cost gross per year cost could exceed per
patient per year exondi administ per kg basi ex-u translarna
approv treatment treatment cost per year
bamboo acquisit intern dmd gene therapi program
compani releas pre-clin data compani rel tight-
lip on-going phase clinic studi compani latest commentari
could see earli clinic data program mid without human data
difficult assess program stack sarepta solid
howev base known pace enrol phase studi pfizer
could second market behind sarepta modest risk-adjust sale forecast
model dmd gene therapi program
rivipansel pan-selectin inhibitor molecul block activ cell adhes
molecul call selectin blood vessel selectin famili three molecul
e- p- l-selectin regul interact cell within blood vessel
promot adhes blood cell white blood cell platelet red blood cell
wall blood vessel rivipansel bind three selectin mainli
e-selectin
sickl cell anemia increas number selectin insid blood vessel
make blood cell prone stick surfac cell caus blood cell
clump blood vessel wall reduc inner space blood
vessel obstruct blood flow lead vaso-occuls crisi voc
turn caus sever attack known sickl cell pain crisi reduc cell adhes
activ inflamm believ contribut reduc blood flow
microvasculatur voc believ rivipansel could first drug
interrupt underli caus voc therebi potenti enabl patient leav
hospit quickli
rivipansel on-going phase studi treat vaso-occlus crisi voc
hospit patient sickl cell diseas data expect readout
model incorpor rel modest revenu assumpt risk-
adjust sale forecast potenti signific upsid data
read posit
strength differenti vaccin portfolio remain underappreci
prevnar remain anchor vaccin busi global sale
vaccin trumenba mening provid smaller contribut
franchis late-stag pipelin two import opportun
next-gener pneumococc vaccin prevnar novel vaccin
clostridium difficil
question outlook prevnar ahead februari
advisori committe immun practic acip meet committe
discuss continu use product adult indic believ prevnar
maintain indic given follow vaccin merck
fda given breakthrough therapi design would surpris us
see acip tell physician longer use prevnar adult come back
coupl year tri re-encourag vaccin adult
merck valent pneumococc vaccin slightli ahead prevnar phase
develop given track record area expect
much behind merck like view superior vaccin allow
transit patient prevnar prevnar without much difficulti
clostridium difficil higher-risk potenti high-reward
opportun also phase data expect compani
struggl make vaccin clostridium difficil target seriou
condit tend occur hospit set lead signific amount
morbid mortal well ad cost healthcar system vaccin
receiv track design fda highlight unmet medic need
hope address potenti prevent develop infect even
high-risk patient could attract long-tail commerci opportun
biosimilar import area potenti upsid take time
acquisit hospira becam lead us manufactur
biosimilar wide rang manufactur commerci challeng prevent
monet acquisit extent initi expect
believ biosimilar final prepar make mark includ us
believ time period hospira deal may final bear fruit
discuss detail recent biosimilar deep dive see one
manufactur expect benefit greater biosimilar uptak
charl martineau univers toronto figur pfizer top beneficiari emerg biosimilar market base
face biosimilar competit enbrel outsid us benefix
genotropin eros exposur substanti lower sale potenti
biosimilar stabl growth biosimilar necessarili investor
look brand pharma compani provid ad
element stori even total sale biosimilar remain small percentag
total compani expect sale base figur also believ wise
move biosimilar portfolio oncolog inflamm immunolog
busi unit latest restructur allow compani better obtain
synergi target physician prescrib brand
biosimilar product therapeut area
ww sale
neutropenia patient
neutropenia patient
epogen procrit
treatment anemia
figur biosimilar sale total sale
biosimilar sale us million left sale right
total sale
corpor action still part stori
start began oper new commerci structur
compos three busi
pfizer biopharmaceut group pbg innov busi incud
previous innov health except consum healthcar hospit
busi unit steril inject anti-infect biosimilar portfolio
incorpor oncolog inflamm immunolog busi unit
upjohn focus off-pat brand gener establish medicin
consum healthcar includ over-the-count medicin
also announc combin consum healthcar
busi joint ventur gsk consum healthcar busi may
separ stand-alone compani futur expect
announc pbg upjohn busi unit near futur wonder
time upjohn unit may also separ rest compani
perhap importantli us compani quit clear past nine
month strategi like involv pursu larg acquisit
believ disrupt often end creat valu sharehold
acquir compani expect compani continu pursu smaller deal
build pipelin encourag larg disrupt deal like
near futur make us comfort recommend share investor
addit hope valu creativ bolt-on acquisit expect continu
provid healthi dividend also repurchas share appropri offer
path investor reward
charl martineau univers toronto upcom catalyst focus pipelin updat
pfe/mrk kgaa bavencio inlyta fda file rcc
osteoarthr chronic low back pain safeti data
vaso-occlus crisi sickl cell patient
dmd earli data first patient therapi
phase data nash
price share
new price target price figur base
blend discount cash flow dcf figur rel valuat
figur
use rel valuat blend calcul target price consist
calcul target price us major pharma compani
dcf forecast cash flow use termin
growth forecast thereaft along wacc wacc consist
use us major pharma compani cover
compani believ closest peer rais termin growth
forecast use note given stronger long-
term outlook see compani
rel valuat util price-to-earnings multipl base new
ep multipl ep consist use
blue sky valuat base greater sale key market
pipelin product ibranc prevnar xtandi eliqui well slightli
higher oper margin profil compani
grey sky valuat base lower sale key market
pipelin product ibranc prevnar xtandi eliqui well slightli
lower oper margin profil compani
figur per share target price base blend dcf
rel valuat
figur dcf sensit analysi show impact
differ wacc perpetu growth assumpt
npv ev lc/share
author report wish acknowledg contribut made selvakumar
nallasami paul singh employe crisil global research analyt
busi divis crisil limit crisil limit third-parti provid off-shore
research servic credit suiss
us million unless otherwis state
sale
us million unless otherwis state
us million unless otherwis state
sale
us million unless otherwis state
eliqui allianc revenu direct
intern medicin
vaccin
oncolog
us million unless otherwis state
inflamm immunolog
diseas
report diseas
us million unless otherwis state
product transit ih eh
us million unless otherwis state
revenu
total incom expens
provis incom tax
compani mention price
